Briumvi-Approved to treat MS.

NOW APPROVED BRIUMVI (ublituximab-xiiy) is now approved for the treatment of relapsing forms of multiple sclerosis (MS), to include clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease, in adults.¹

Medicare finalizes 4.5% physician pay cut

Patsy Newitt – Wednesday, November 2nd, 2022    Medicare’s physician fee schedule final rule, released Nov. 1, will reduce the physician pay conversion factor by 4.48 percent to $33.06.  The conversion factor used to calculate physician reimbursement will...

VACCINES NEVER PREVENTED THE TRANSMISSION OF COVID

In late 2021 and early 2022, it was commonplace for journalists and public intellectuals to demonize and shame “the unvaccinated,” a group that in the United States was disproportionately low income. The New York Times ran pieces like “I’m Furious at the...